{"product_id":"tevapharm-bcg-matrix","title":"Teva Pharmaceutical Industries Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eTeva Pharmaceutical Industries shows mixed positioning in our BCG preview: legacy generics act like Cash Cows with steady cash generation, specialty drugs and biologics are emerging Stars, while some late-stage generics risk sliding into Dogs amid pricing pressure and competition. This snapshot hints at where R\u0026amp;D and capital allocation could drive growth or require divestment. Dive deeper into this company’s BCG Matrix and gain a clear view of where its products stand—Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAustedo Family\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of end-2025 Austedo (including XR) is Teva’s primary growth engine with global revenues around $2.26 billion and double-digit year-over-year growth into 2026.\u003c\/p\u003e\n\u003cp\u003eIt holds dominant share in tardive dyskinesia and Huntington’s chorea, driven by high adherence and clinical positioning, while about 85% of eligible patients remain untreated.\u003c\/p\u003e\n\u003cp\u003eOngoing investment in marketing and physician education is required to capture that untapped pool and sustain growth; 2025 marketing spend rose ~12% to support uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAjovy Migraine Therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAjovy (fremanezumab) is a Star for Teva, holding a 33.3% share of the US subcutaneous anti-CGRP market by late 2025 and posting 30% annual growth to $673 million in 2025 sales.\u003c\/p\u003e\n\u003cp\u003ePediatric indication expansions and availability in 43+ countries fuel uptake, but Teva must keep aggressive placement, promotion, and international expansion to defend share vs rival CGRP inhibitors and fully capture high-growth markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUzedy Schizophrenia Treatment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUzedy Schizophrenia Treatment is Teva’s fastest-growing long-acting injectable, with revenues jumping 63% to $191 million by year-end 2025.\u003c\/p\u003e\n\u003cp\u003eSince launch and a label expansion to include Bipolar 1 Disorder, Uzedy captured over 60% of the risperidone LAI market share.\u003c\/p\u003e\n\u003cp\u003eClassified as a BCG Matrix Star, Uzedy needs continued capital investment to sustain market penetration and evolve into a long-term cash generator for Teva.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilars Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTeva’s biosimilars segment is a Star after the 2025 launches of Selarsdi and Epysqli, targeting combined addressable markets of roughly $18–22 billion previously served by Stelara (Janssen) and Soliris (Alexion) as of 2024 sales data.\u003c\/p\u003e\n\u003cp\u003eTeva now runs one of the largest biosimilar pipelines with \u0026gt;15 programs, a strategic hedge against mid-single-digit annual erosion in its generics revenue; biosimilars drove an estimated $1.1bn in 2025 revenue.\u003c\/p\u003e\n\u003cp\u003eSignificant ongoing investment—R\u0026amp;D and EU\/US regulatory spend—remains required to win tender pricing and navigate interchangeability rules, keeping margins pressured despite high revenue growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 launches: Selarsdi + Epysqli\u003c\/li\u003e\n\u003cli\u003eAddressable market: ~$18–22bn\u003c\/li\u003e\n\u003cli\u003ePipeline: \u0026gt;15 biosimilar programs\u003c\/li\u003e\n\u003cli\u003e2025 biosimilars rev: ~$1.1bn\u003c\/li\u003e\n\u003cli\u003eNeed: heavy R\u0026amp;D and regulatory spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplex Generics Segment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTeva’s Complex Generics segment—covering high-barrier products like the generic EpiPen—sits in the BCG Stars quadrant: high growth and high market share due to limited competition and global demand rising ~6–8% annually (2024 industry estimate).\u003c\/p\u003e\n\u003cp\u003eThese products need advanced manufacturing and R\u0026amp;D, raising per-unit gross margins to mid-30s% versus low-20s% for commodity generics, supporting Teva’s leadership in hard-to-replicate molecules.\u003c\/p\u003e\n\u003cp\u003eBy prioritizing complex molecules, Teva secures durable market share, benefits from pricing power, and captures faster revenue growth than plain generics.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth ~6–8% p.a. (2024 industry)\u003c\/li\u003e\n\u003cli\u003eMid-30s% gross margins vs ~20s% for standard generics\u003c\/li\u003e\n\u003cli\u003eSignificant capex\/R\u0026amp;D for complex manufacturing\u003c\/li\u003e\n\u003cli\u003eLimited competition → strong pricing power\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTeva's Stars Fuel $4.3B 2025: Austedo \u0026amp; Ajovy Lead, Biosimilars \u0026amp; Generics Rising\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTeva’s Stars (Austedo, Ajovy, Uzedy, biosimilars, complex generics) drove ~ $4.3bn revenue in 2025 with double-digit growth for Austedo (≈$2.26bn) and Ajovy ($673m, 33% US share); biosimilars ~$1.1bn and complex generics margin mid-30s%. Continued heavy marketing, R\u0026amp;D and regulatory spend required to convert high share into long-term cash flow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2025 rev\u003c\/th\u003e\n\u003cth\u003eGrowth\/share\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAustedo\u003c\/td\u003e\n\u003ctd\u003e$2.26bn\u003c\/td\u003e\n\u003ctd\u003eDD%\/primary engine\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAjovy\u003c\/td\u003e\n\u003ctd\u003e$673m\u003c\/td\u003e\n\u003ctd\u003e30%\/33% US\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilars\u003c\/td\u003e\n\u003ctd\u003e$1.1bn\u003c\/td\u003e\n\u003ctd\u003ePipeline\u0026gt;15\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComplex generics\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003emargins mid-30s%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG-matrix review of Teva’s portfolio: Stars, Cash Cows, Question Marks, Dogs with investment, hold, divest guidance and trend context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix placing Teva’s units in clear quadrants for quick strategic decisions and executive alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Generics Powerhouse\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva Pharmaceuticals, the world’s largest generic drug maker, held a portfolio of over 3,500 products and roughly 12–14% global market share by prescriptions as of Q3 2025, making this a classic Cash Cow.\u003c\/p\u003e\n\u003cp\u003eThe mature generics unit produced steady operating cash flow—about $2.6 billion trailing twelve months (TTM) in 2025—funding R\u0026amp;D and servicing corporate debt after Allergan and specialty write-downs.\u003c\/p\u003e\n\u003cp\u003eGrowth is low amid intense pricing pressure and margin compression; still, volume—hundreds of millions of prescriptions annually—keeps it the company’s primary financial backbone.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOver-The-Counter (OTC) Business\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva’s global OTC franchise is a $1.1 billion business (2025 sales) that delivers stable, high-margin cash flow, outpacing broader OTC market growth of ~2–3% with Teva at ~4.5% CAGR (2022–2025).\u003c\/p\u003e\n\u003cp\u003eThese branded OTCs need far less promotional spend than Rx launches, keeping gross margins higher—estimated 2025 gross margin ~48% vs company average ~32%.\u003c\/p\u003e\n\u003cp\u003eManagement is actively milking this mature segment: OTC free cash flow helps fund R\u0026amp;D and launches under the Pivot to Growth, covering an estimated $300–400 million of near-term investment through 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMature Respiratory Franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMature respiratory franchise: established brands like ProAir and Qvar retain strong share in a stable, low-growth market, generating steady margins despite some generic entrants.\u003c\/p\u003e\n\u003cp\u003eThese products need little capex or new infrastructure, acting as classic Cash Cows and supporting Teva’s operations; they helped deliver $2.39 billion in operating cash flow at year-end 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBendeka and Treanda\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBendeka (bendamustine) and Treanda (bendamustine) are Teva cash cows in chronic lymphocytic leukemia and non-Hodgkin lymphoma, holding high niche market share—Teva reported oncology generics revenue of about $1.1bn in 2024, with bendamustine among top sellers in its class.\u003c\/p\u003e\n\u003cp\u003eBoth drugs are in mature lifecycle with low growth but strong margins; gross margins for Teva’s established injectables averaged ~45% in 2024, letting these products generate steady free cash flow.\u003c\/p\u003e\n\u003cp\u003eThey need minimal capex—manufacturing and regulatory upkeep only—so Teva can reinvest proceeds into R\u0026amp;D; Teva’s 2024 R\u0026amp;D spend was $1.2bn, funded partly by such cash flows.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh niche share; top-selling bendamustine in 2024\u003c\/li\u003e\n\u003cli\u003eMature stage: low revenue growth, high margin (~45%)\u003c\/li\u003e\n\u003cli\u003eMinimal capex; steady free cash flow\u003c\/li\u003e\n\u003cli\u003eFunds redirected to R\u0026amp;D: Teva 2024 R\u0026amp;D ~$1.2bn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActive Pharmaceutical Ingredients (TAPI)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTeva’s Active Pharmaceutical Ingredients (TAPI) unit acted as a Cash Cow in 2025, supplying small-molecule APIs to internal divisions and third-party clients while retaining a global market-leading share and steady margins in a mature market.\u003c\/p\u003e\n\u003cp\u003ePlanned full divestiture began in 2025; proceeds are earmarked to shore up the balance sheet and cut net debt — Teva reported net debt down roughly $1.1 billion by Q3 2025 versus year-end 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh market share — global small-molecule API leader\u003c\/li\u003e\n\u003cli\u003eConsistent margins — mature industry cash generator\u003c\/li\u003e\n\u003cli\u003e2025 divestiture proceeds used to reduce net debt (~$1.1B decline YTD)\u003c\/li\u003e\n\u003cli\u003eServed internal and external manufacturers, steady revenue stream\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTeva’s cash engines: $2.6B OpCF, $1.1B OTC \u0026amp; oncology, margins ~45–48%, $1.1B debt cut\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTeva’s mature generics, OTCs, respiratory brands, oncology injectables and TAPI generated steady cash: ~ $2.6B TTM operating cash flow (2025), OTC sales $1.1B (2025), oncology generics ~$1.1B (2024), gross margins ~45% injectables \/ ~48% OTC, R\u0026amp;D $1.2B (2024); TAPI divestiture cut net debt ≈ $1.1B YTD 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOp CF (TTM 2025)\u003c\/td\u003e\n\u003ctd\u003e$2.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTC Sales 2025\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology Generics 2024\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margins\u003c\/td\u003e\n\u003ctd\u003eInjectables 45% \/ OTC 48%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D 2024\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt reduction YTD 2025\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eTeva Pharmaceutical Industries BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the final Teva Pharmaceutical Industries BCG Matrix you'll receive after purchase—no watermarks, no demo content—just a fully formatted, market-informed report that maps Teva’s product portfolio into Stars, Cash Cows, Question Marks, and Dogs for immediate strategic use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748135186809,"sku":"tevapharm-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/tevapharm-bcg-matrix.png?v=1772205213","url":"https:\/\/matrixbcg.com\/products\/tevapharm-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}